Molecular Formula | C186H286N50O62S |
Molar Mass | 4244.60796 |
Melting Point | >209°C (dec.) |
Solubility | Acetonitrile (Slightly), Water (Slightly) |
Appearance | Solid |
Color | White to Off-White |
Storage Condition | Refrigerator, under inert atmosphere |
Physical and Chemical Properties | White powder, soluble in methanol, ethanol, DMSO and other organic solvents. |
Use | Treatment of type 2 diabetes mellitus
Anti-HIV drugs |
In vitro study | A cell-cell fusion assay reveals that the effective concentration for achieving 50% inhibition (IC 50 ) of Enfuvirtide is 23 ± 6 nM. IFN-λs (1, 2, or 3) or the antiretrovirals (AZT, Efavirenz, Indinavir, and Enfuvirtide) significantly inhibita the expression of HIV p24 antigen and Gag gene in macrophages. IFN-λs (1, 2, or 3) also enhanced the anti-HIV (Bal) effect of AZT, Efavirenz, Indinavir, and Enfuvirtide. |
In vivo study | Enfuvirtide has a T 1/2 of 3.8 h. |
Application | Exenatide acetate is a synthetic GLP-1 (glucagon-like peptide) analog composed of 39 amino acids. Exenatide acetate is an enterohypoglycemic agent that can mimic glucose-dependent insulin secretion enhancement and other antihyperglycemic effects of incretin. |
Overview | The amino acid sequence of exenatide acetate partially overlaps with human GLP-1. Exenatide acetate has been shown to bind to and activate known human GLP-1 receptors in vitro. This implies an increase in glucose-dependent insulin synthesis and in vivo endocrine insulin by pancreatic beta cells, including cAMP (cyclic adenosine monophosphate) or other intracellular signaling mechanisms. |
biological activity | Enfuvirtide (T20; DP178) acetate is an inhibitory peptide against HIV-1 fusion. |
target | HIV fusion |
use | exenatide acetate can be used as incretin. |